| melanoma
Imlygic vs Tafinlar + Mekinist
Side-by-side clinical, coverage, and cost comparison for melanoma.Deep comparison between: Imlygic vs Tafinlar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTafinlar has a higher rate of injection site reactions vs Imlygic based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tafinlar but not Imlygic, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Imlygic
Tafinlar
At A Glance
Intralesional injection
Every 2-3 weeks
Oncolytic viral therapy
Oral
Twice daily
BRAF kinase inhibitor
Indications
- Melanoma
- melanoma
- Non-Small Cell Lung Carcinoma
- Anaplastic thyroid carcinoma
- Low grade glioma
- Solid Neoplasm
Dosing
Melanoma Initial dose up to 4 mL at 1 million PFU/mL intralesionally; second dose 3 weeks later up to 4 mL at 100 million PFU/mL; all subsequent doses every 2 weeks up to 4 mL at 100 million PFU/mL.
Melanoma 150 mg orally twice daily as single agent or in combination with trametinib 2 mg once daily, oral route.
Non-Small Cell Lung Carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Anaplastic thyroid carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Low grade glioma Weight-based dosing in pediatric patients (20-150 mg twice daily) in combination with trametinib, oral route.
Solid Neoplasm 150 mg orally twice daily in combination with trametinib 2 mg once daily in adults; weight-based dosing in pediatric patients >= 1 year, oral route.
Contraindications
- Immunocompromised patients, including those with primary or acquired immunodeficiency, leukemia, lymphoma, AIDS or other clinical manifestations of HIV infection, or on immunosuppressive therapy
- Pregnant patients
—
Adverse Reactions
Most common (>=25%) Fatigue, chills, pyrexia, nausea, influenza-like illness, injection site pain
Serious Cellulitis (most common grade 3+ reaction), herpetic infection, injection site complications
Postmarketing Disseminated herpetic infections, including serious and fatal cases in immunocompromised patients
Most common (>= 20%) Pyrexia, rash, hyperkeratosis, headache, arthralgia, papilloma, alopecia, palmar-plantar erythrodysesthesia syndrome, chills, cough, nausea, vomiting, diarrhea, fatigue, dry skin, myalgia, constipation, decreased appetite, edema, hemorrhage, dyspnea, musculoskeletal pain, abdominal pain, epistaxis, dermatitis acneiform
Serious New primary malignancies (cutaneous and non-cutaneous RAS mutation-positive), hemorrhage, cardiomyopathy, uveitis, serious febrile reactions, serious skin toxicities including SCAR, hyperglycemia, glucose-6-phosphate dehydrogenase deficiency, hemophagocytic lymphohistiocytosis
Pharmacology
Oncolytic viral therapy; genetically modified live attenuated HSV-1 that replicates within tumors causing lysis and release of tumor-derived antigens, and produces GM-CSF to promote an antitumor immune response; exact mechanism of action is unknown.
Dabrafenib is a BRAF kinase inhibitor that targets mutated BRAF V600E, V600K, and V600D enzymes, inhibiting cell growth in BRAF V600 mutation-positive tumors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Imlygic
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
Tafinlar
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Imlygic
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tafinlar
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Imlygic
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tafinlar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tafinlar.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ImlygicView full Imlygic profile
TafinlarView full Tafinlar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.